Literature DB >> 666989

Contractile protein antigens in the cells of malignant melanoma of the choroid and their diagnostic significance.

A H Rahi, A Garner, A H Malaty.   

Abstract

Sera from patients with proved and suspected melanoma of the uvea and from patients with innocuous uveal naevi were found by immunohistological techniques to have an affinity for the cytoplasm of malignant choroidal melanoma cells in an appreciable proportion of cases. The responsible antibodies were subsequently shown to react with smooth muscle protein in a variety of tissues and not to be melanoma-specific. It was also shown by electron microscopy that microfilaments consistent with contractile protein are a feature of the cytoplasm of malignant choroidal melanoma cells. The latter observations, which do not appear to have been reported previously, mean that false positives are to be expected if immunodiagnostic techniques are used for the recognition of malignant disease of the uvea, especially as smooth muscle antibodies can occur in non-neoplastic ocular diseases.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 666989      PMCID: PMC1043242          DOI: 10.1136/bjo.62.6.394

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  15 in total

Review 1.  Immunofluorescence studies on the structure of actin filaments in tissue culture cells.

Authors:  E Lazarides
Journal:  J Histochem Cytochem       Date:  1975-07       Impact factor: 2.479

2.  An in vitro model of phagocytosis in bovine and human retinal pigment epithelium.

Authors:  L Feeney; R N Mixon
Journal:  Exp Eye Res       Date:  1976-05       Impact factor: 3.467

Review 3.  Stimulated neutrophil locomotion: chemokinesis and chemotaxis.

Authors:  E L Becker
Journal:  Arch Pathol Lab Med       Date:  1977-10       Impact factor: 5.534

4.  Immunological investigations in uveitis.

Authors:  A H Rahi; E J Holborow; E S Perkins; Y Y Gungen; W J Dinning
Journal:  Trans Ophthalmol Soc U K       Date:  1976-04

5.  Characterisation of immunofluorescent heterophile antibodies which may be confused with autoantibodies.

Authors:  B R Hawkins; B L McDonald; R L Dawkins
Journal:  J Clin Pathol       Date:  1977-04       Impact factor: 3.411

6.  Autoimmune hepatitis. Immunofluorescence reactions with cytoplasm of smooth muscle and renal glomerular cells.

Authors:  S Whittingham; I R Mackay; J Irwin
Journal:  Lancet       Date:  1966-06-18       Impact factor: 79.321

7.  Immunofluorescent detection of antibodies to ocular melanomas.

Authors:  I G Wong; R M Oskvig
Journal:  Arch Ophthalmol       Date:  1974-08

8.  Antibody to smooth muscle in patients with liver disease.

Authors:  G D Johnson; E J Holborow; L E Glynn
Journal:  Lancet       Date:  1965-10-30       Impact factor: 79.321

9.  Experimental smooth muscle antibodies.

Authors:  A K Li; P S Trenchev; E J Holborow; C Newsome; A T Wynne
Journal:  Clin Exp Immunol       Date:  1977-02       Impact factor: 4.330

10.  The specificity of anti-actin serum.

Authors:  P Trenchev; E J Holborow
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

View more
  4 in total

1.  Lymphoproliferative response as an index of cellular immunity in malignant melanoma of the uvea and its correlation with the histological features of the tumour.

Authors:  M S Sunba; A H Rahi; G Morgan; E J Holborow
Journal:  Br J Ophthalmol       Date:  1980-08       Impact factor: 4.638

2.  Early diagnosis of choroidal melanoma.

Authors: 
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

3.  Tumours of the anterior uvea. III. Oxytalan fibres in the differential diagnosis of leiomyoma and malignant melanoma of the iris.

Authors:  M S Noor Sunba; A H Rahi; A Garner; R A Alexander; G Morgan
Journal:  Br J Ophthalmol       Date:  1980-11       Impact factor: 4.638

4.  Antibodies to skeletal muscle actin and their reactivity with malignant melanoma of the choroid.

Authors:  A Malaty; A Rahi; A Garner
Journal:  Br J Ophthalmol       Date:  1980-03       Impact factor: 4.638

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.